208 related articles for article (PubMed ID: 37290440)
1. New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML; Liu Y; Harkins SK; Weinstock DM; Yang L; Stevenson KE; Plana OD; Dong J; Cirka H; Jones KL; Virtanen AT; Gupta DG; Ceas A; Lawney B; Yoda A; Leahy C; Hao M; He Z; Choi HG; Wang Y; Silvennoinen O; Hubbard SR; Zhang T; Gray NS; Li LS
Cell Chem Biol; 2023 Jun; 30(6):618-631.e12. PubMed ID: 37290440
[TBL] [Abstract][Full Text] [Related]
2. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
3. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Wu SC; Li LS; Kopp N; Montero J; Chapuy B; Yoda A; Christie AL; Liu H; Christodoulou A; van Bodegom D; van der Zwet J; Layer JV; Tivey T; Lane AA; Ryan JA; Ng SY; DeAngelo DJ; Stone RM; Steensma D; Wadleigh M; Harris M; Mandon E; Ebel N; Andraos R; Romanet V; Dölemeyer A; Sterker D; Zender M; Rodig SJ; Murakami M; Hofmann F; Kuo F; Eck MJ; Silverman LB; Sallan SE; Letai A; Baffert F; Vangrevelinghe E; Radimerski T; Gaul C; Weinstock DM
Cancer Cell; 2015 Jul; 28(1):29-41. PubMed ID: 26175414
[TBL] [Abstract][Full Text] [Related]
4. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
[TBL] [Abstract][Full Text] [Related]
5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
6. Targeting JAK2 in the therapy of myeloproliferative neoplasms.
Reddy MM; Deshpande A; Sattler M
Expert Opin Ther Targets; 2012 Mar; 16(3):313-24. PubMed ID: 22339244
[TBL] [Abstract][Full Text] [Related]
7. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
[TBL] [Abstract][Full Text] [Related]
8. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
9. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
10. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
11. Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.
Downes CEJ; McClure BJ; Bruning JB; Page E; Breen J; Rehn J; Yeung DT; White DL
NPJ Precis Oncol; 2021 Aug; 5(1):75. PubMed ID: 34376782
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
Silvennoinen O; Hubbard SR
Cancer Cell; 2015 Jul; 28(1):1-2. PubMed ID: 26175407
[TBL] [Abstract][Full Text] [Related]
13. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
14. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
16. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
17. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Atallah E; Verstovsek S
Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
[TBL] [Abstract][Full Text] [Related]
18. Computational modeling and in vitro evaluation identified natural product-Z218 as a novel Janus kinase 2 (JAK2) inhibitor to combat β-thalassemia.
Shaikh A
Biotechnol Appl Biochem; 2023 Aug; 70(4):1450-1459. PubMed ID: 36999639
[TBL] [Abstract][Full Text] [Related]
19. Effect of mutation order on myeloproliferative neoplasms.
Ortmann CA; Kent DG; Nangalia J; Silber Y; Wedge DC; Grinfeld J; Baxter EJ; Massie CE; Papaemmanuil E; Menon S; Godfrey AL; Dimitropoulou D; Guglielmelli P; Bellosillo B; Besses C; Döhner K; Harrison CN; Vassiliou GS; Vannucchi A; Campbell PJ; Green AR
N Engl J Med; 2015 Feb; 372(7):601-612. PubMed ID: 25671252
[TBL] [Abstract][Full Text] [Related]
20. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
